Summary
Molsidomine (N-carboxy-3-morpholino-sydnonimine-ethylester; Cassella-Riedel Pharma GmbH, Frankfurt/M. FRG) has an antianginal effect for up to 3–5 h after oral administration of 2 mg Corvaton [1]. Plasma levels of the parent drug can be measured during this interval. A new galenic formulation (Corvaton retard) has been developed to prolong the duration of the therapeutic action and to improve patient compliance. The present study was carried out to establish whether the in vitro dissolution profile of the tablet was reflected in vivo, thus permitting prediction of plasma molsidomine levels in patients with coronary heart disease.
This is a preview of subscription content, log in via an institution to check access.
References
Strasser R, Klepzig H, Ostrowski J, Resag K (1983) Molsidomin bei koronarer Herzkrankheit. Klinisch pharmako-kinetische Korrelationsstudie über die Wirkung der oralen und sublingualen Therapie. Dtsch Med Wochenschr 125: 156–158
Dell D, Chamberlain J (1978) Determination of molsidomine in plasma by high-performance liquid column chromatography. J Chromatogr 146: 465–472
Voegele D, Ostrowski J, Stauch M, Brockmeier D (1985) In vivo relevance of a controlled oral release system of molsidomine. Die Pharmazeutische Industrie 47: 524–527
Ostrowski J, Voegele D, Brockmeier D, v. Hattingberg HM, Blasini R, Bruegmann U, Resag K, Rudolph W, Weidemann H (1983) In vivo-Relevanz von in vitro-Liberationsergebnissen. Acta Pharm Technol 29: 295–301
Feldmann U, Schneider B, Klinkers H (1981) A multivariable approach for the biometric comparison of analytical methods in clinical chemistry. J Clin Chem Clin Biochem 19: 121–137
Ostrowski J (1978) Zur Pharmakokinetik von Corvaton beim Menschen. Lochner W, Bender F (eds) Urban & Schwarzenberg, pp 69, Munich
Brockmeier D, Dengler HJ, Voegele D (1985) In vitro-in vivo correlation, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur J Clin Pharmacol 28: 291–300
Voegele D, Ostrowski J (1984) Charakterisierung einer den Wirkstoff Molsidomin gesteuert freisetzenden oralen Zubereitung (Corvaton CoRS). Die Pharmazeutische Industrie 46: 1267–1270
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ostrowski, J., Gaul, G., Voegele, D. et al. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease. Eur J Clin Pharmacol 28, 611–613 (1985). https://doi.org/10.1007/BF00544076
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544076